BACKGROUND: The relationship between chromosome 18q allelic imbalance (AI) and survival in colorectal cancer (CRC) is unclear, and study design may have contributed to inconsistent results previously reported. PATIENTS AND METHODS: Two hundred and eighty tumours from CRC patients participating in a molecular sub-study from a single multicentre trial of adjuvant intra-portal 5-fluorouracil were genotyped at 5 chromosome 18q microsatellite markers, blinded to clinical data and prospective to follow-up. The relationship between overall survival and AI was examined. RESULTS: Two hundred and fifty-five tumours were informative for AI. The overall rate of AI was 49%. AI was not associated with age, tumour site or size. There was no difference in five-year survival rate between patients with (60.0% SE 5.2%) and without AI (61.4% SE 5.0%), even after correcting for covariates (HR=1.17, 95%CI:0.79-1.74, p=0.4). CONCLUSION: Our data does not [corrected] support chromosome 18q AI as an important marker of survival in the adjuvant setting. It should not, therefore, be used outside clinical trials.

Type

Journal article

Journal

Anticancer Res

Publication Date

01/2007

Volume

27

Pages

627 - 633

Keywords

Adolescent, Adult, Aged, Allelic Imbalance, Chromosomes, Human, Pair 18, Colorectal Neoplasms, Double-Blind Method, Female, Genotype, Humans, Kaplan-Meier Estimate, Male, Microsatellite Repeats, Middle Aged, Prognosis, Prospective Studies